Skip to main content
Clinical Trials/NCT02546401
NCT02546401
Completed
Phase 3

Comparison of Injection of an Analogue Bolus of Insulin Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump.

University Hospital, Brest1 site in 1 country22 target enrollmentSeptember 1, 2015

Overview

Phase
Phase 3
Intervention
Insulin Aspart
Conditions
Diabetes Type 1
Sponsor
University Hospital, Brest
Enrollment
22
Locations
1
Primary Endpoint
Area Under Curve (AUC) of glycemia
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

The current study focuses on terms of use of Insulin Aspart, fast analogue of human insulin and commonly used in the treatment of type 1 diabetes, where it obtained the marketing authorization for this indication. In the patient who have an insulin pump, insulin Aspart is given daily like a pre-prandial bolus (just before the meal). However, many patients perform their bolus after the meal. However this insulin administration modality is not clearly studied in the literature.

Detailed Description

The functional insulin therapy is a method for adjusting insulin doses which tends to mimic the physiology, especially when food intake with proportional dose calculation to the amount of carbohydrates ingested by the use of ratios. This method of adaptation, increasingly used in France, is an extension in the use of subcutaneous insulin pump with a more precise determination of bolus doses with meals, and use of aids dose calculations (assistant wizard for instance). In practice every day, some patients perform their bolus immediately after eating, not just before, allowing them to know exactly the amount of ingested carbohydrates and not the one provided in advance. This study is very interesting because it allows to compare the injection of an analogous bolus of fast insulin before and after the meal.

Registry
clinicaltrials.gov
Start Date
September 1, 2015
End Date
March 1, 2016
Last Updated
5 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Major patients with type 1 diabetes treated with insulin pump.

Exclusion Criteria

  • Unbalanced diabetes,
  • Ongoing pregnancy known,
  • Gastrointestinal neuropathy known,
  • Chronic medical illness and psychiatric

Arms & Interventions

Group 1

Patients will perform their bolus for 2 weeks before meals (BE) and for 2 weeks after meals (AF). Intervention: drug (insulin Aspart)

Intervention: Insulin Aspart

Group 2

Patients will perform their bolus for 2 weeks after meals (AF) and for 2 weeks before meals (BE). Intervention: drug (insulin Aspart)

Intervention: Insulin Aspart

Outcomes

Primary Outcomes

Area Under Curve (AUC) of glycemia

Time Frame: During 14 days

Area Under Curve (AUC) recording blood glucose performed continuously over 14 days, with baseline to 1,40g/L (in order not to consider hypoglycemia)

Secondary Outcomes

  • Mean Amplitude of Glycemic excursions (MAGE) = measure of glycemia instability(During 14 days)
  • Area Under Curve (AUC) during 4H after a high-fat meal(4 hours)

Study Sites (1)

Loading locations...

Similar Trials